Abstract 380P
Background
Globally, there are roughly 476 million indigenous peoples in 90 nations worldwide, representing a wide range of cultures, dialects, and spirits. India has the world's second-highest concentration of tribal people after African countries. Spread across 705 tribes accounting for 8.6% of the country’s population, over 104 million tribal people live; making India home to numerous tribes with diverse origins, customs, and societal practices. Government of India have identified Primitive tribal communities on the basis of their pre-agricultural level of technology, extremely low level of literacy, and small, stagnant, or diminishing population. This epidemiological cross- sectional study was designed to assess the prevalence of oral cancer and its awareness among Irula tribes of South India.
Methods
A cross sectional descriptive study was conducted among 200 Irula tribes using a pretested Questionnaire, which included demographic information, tobacco habits, its frequency, and cancer awareness. Oral examination to assess oral cancer was done by a single examiner. SPSS version 21 was used to analyse the collected data.
Results
The findings revealed that 87% of the 200 study participants had no formal education and 38% had never visited a dentist. 64.5% practised indigenous brushing. There were 52% of oral mucosal lesions and 6% of malignant oral tumours found. This community had a very high prevalence of periodontal disease, tobacco chewing, and deeply ingrained beliefs and customs about dentition and dental treatment. The prevalence of oral mucosal lesions in the study population was due to tobacco use and a lack of knowledge about the harmful effects of the products used.
Conclusions
Although the problems associated with smoking and chewing tobacco are extensively documented in the literature, it is worrying that this indigenous group is not aware of the consequences. The public should be made aware of these concerns, especially those in high-risk groups, according to health specialists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract